ischaemic stoke
Conditions
Interventions
Group B:Berberine 0.5 g, orally taken three times daily and Atorvastatin 10mg once daily and Aspirine 0.1 g once daily for 1 year
Group P:Placebo 0.5 g, orally taken three times daily and Atorvastatin 10mg once daily and Aspirine 0.1 g once daily for 1 year
Sponsors
Second Affiliated Hospital of Jinan University
Eligibility
Sex/Gender
Female
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. male and female aged 35 to 75 years old; 2. patients with symptomatic cerebral infarction in the previous 2 weeks to 3 months; 3. patients with focal signs that had lasted >=24 hours and ischemic infarction-related focal lesion compatible with their signs and symptoms defined by computed tomography or magnetic resonance imaging; 4. patients provided written, informed consent; 5. patients with one or more risk factor for cerebrovascular disease that can be treated.
Exclusion criteria
Exclusion criteria: 1. patients with large area of cerebral infarction or ina coma; 2. patients with angioplasty of intra and exterior cerebral arterial stenosis; 3. women with pregnancy or lactation; 4. history of sensitivity to any of the medicine in the trial; 5. patients with cerebral infarction exception to atherosclerosis such as cardioembolic stroke, arteritis, polycythemia vera, crescent cell anaemia, thrombocythemia, purpura haemorrhagica, DIC, moyamoya disease, intracranial vascular malformation, intracranial aneurysm; 6. severe complication such as cardiac, renal, hepatic, lung or blood disorders or malignancy that can’t accomplish 1 year follow-up; current peptic ulceration; 7. psychiatric disease; 8. history of bleeding diathesis or systemic bleeding; 9. history of intracranial hemorrhage; 10. patients or their dependants disagree or reject to sign; 11. modified Rankin Scale(mRS) score of 4 or more; 12. water drinking test>=4; 13. enrollment<=3 months in any other clinical trial; 14. patients with G-6-PD; 15. judgment by investigators to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of cardiovascular events;Incidence of peripheral arteries diseases;Recurrence rate of stroke in 1 year; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum triglyceride and cholesterol, low density lipoprotein concentration; | — |
Countries
China
Contacts
Public ContactYi Guo
Outcome results
None listed